CARMA FUND Management

CARMA FUND Management operates as a specialized investment vehicle focused on early-stage opportunities within the Life Science and Healthcare technology sectors. Established with its initial closing in June 2022, the fund currently manages assets totaling €50 million. With dual headquarters in Munich and Frankfurt am Main, CARMA strategically positions itself within Germany's leading innovation hubs, leveraging the robust healthcare ecosystem and research infrastructure present in these regions.

The fund's investment philosophy centers on identifying transformative technologies with significant market potential across the healthcare continuum. CARMA typically engages at the critical early development stages where capital can substantially accelerate innovation trajectories. Their portfolio reflects a balanced approach to risk management while pursuing opportunities in areas including digital health solutions, medical devices, diagnostic platforms, and therapeutic innovations that address substantial unmet medical needs.

Led by a team with extensive experience in both healthcare and venture capital, CARMA brings valuable industry connections and operational expertise to portfolio companies. The fund's advisors and partners maintain strong relationships with leading German research institutions, university hospitals, and the broader European healthcare innovation network. This collaborative approach enables portfolio companies to access strategic guidance beyond mere financial investment, including regulatory navigation, clinical validation strategies, and market entry planning.

Since its inception, CARMA has demonstrated a commitment to supporting ventures that combine scientific excellence with commercial viability. The fund's investment criteria emphasize scalable business models, strong intellectual property positions, and teams with complementary skill sets capable of executing ambitious growth strategies. Looking forward, CARMA aims to expand its investment capacity and geographic reach while maintaining its core focus on advancing healthcare innovations that improve patient outcomes and healthcare system efficiency across European and global markets.